Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy

Full text
Author(s):
Nars, Mariana S. [1] ; Kaneno, Ramon [1, 2]
Total Authors: 2
Affiliation:
[1] UNESP Univ Estadual Paulista, Inst Biosci, Dept Microbiol & Immunol, Sao Paulo - Brazil
[2] UNESP Univ Estadual Paulista, Sch Med, Dept Pathol, Sao Paulo - Brazil
Total Affiliations: 2
Document type: Review article
Source: International Journal of Cancer; v. 132, n. 11, p. 2471-2478, JUN 1 2013.
Web of Science Citations: 50
Abstract

Given that cancer is one of the main causes of death worldwide, many efforts have been directed toward discovering new treatments and approaches to cure or control this group of diseases. Chemotherapy is the main treatment for cancer; however, a conventional schedule based on maximum tolerated dose (MTD) shows several side effects and frequently allows the development of drug resistance. On the other side, low dose chemotherapy involves antiangiogenic and immunomodulatory processes that help host to fight against tumor cells, with lower grade of side effects. In this review, we present evidence that metronomic chemotherapy, based on the frequent administration of low or intermediate doses of chemotherapeutics, can be better than or as efficient as MTD. Finally, we present some data indicating that noncytotoxic concentrations of antineoplastic agents are able to both up-regulate the immune system and increase the susceptibility of tumor cells to cytotoxic T lymphocytes. Taken together, data from the literature provides us with sufficient evidence that low concentrations of selected chemotherapeutic agents, rather than conventional high doses, should be evaluated in combination with immunotherapy. (AU)

FAPESP's process: 09/18331-8 - Chemoimmunomodulation with antineoplastic agents and generation of dendritic cell vaccine
Grantee:Ramon Kaneno
Support Opportunities: Regular Research Grants
FAPESP's process: 09/18434-1 - Effect of minimum effective doses of paclitaxel and 5-aza-2'-deoxycytidine on the function of human dendritic cells and on immunogenicity of colorectal cancer cells
Grantee:Mariana de Souza Nars
Support Opportunities: Scholarships in Brazil - Scientific Initiation